Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antipsychotic medication
phenothiazine derivative |
| gptkbp:ATCCode |
N05AA01
|
| gptkbp:brand |
gptkb:Largactil
gptkb:Thorazine |
| gptkbp:CASNumber |
50-53-3
|
| gptkbp:chemicalFormula |
C17H19ClN2S
|
| gptkbp:color |
white to pale yellow (powder)
|
| gptkbp:contraindication |
coma
bone marrow depression CNS depression |
| gptkbp:developedBy |
gptkb:Rhône-Poulenc
|
| gptkbp:discoveredBy |
gptkb:Paul_Charpentier
|
| gptkbp:discoveredIn |
1950
|
| gptkbp:eliminationHalfLife |
30 hours
|
| gptkbp:excretion |
urine
bile feces |
| gptkbp:firstAntipsychotic |
true
|
| https://www.w3.org/2000/01/rdf-schema#label |
chlorpromazine
|
| gptkbp:includedIn |
gptkb:World_Health_Organization's_List_of_Essential_Medicines
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
dopamine D2 receptor antagonist
antagonist at histamine, muscarinic, and adrenergic receptors |
| gptkbp:MeSH_ID |
D002811
|
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
318.86 g/mol
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:PubChem_CID |
2726
DB00477 |
| gptkbp:routeOfAdministration |
oral
intramuscular intravenous |
| gptkbp:sideEffect |
weight gain
hypotension sedation photosensitivity extrapyramidal symptoms neuroleptic malignant syndrome anticholinergic effects |
| gptkbp:solubility |
slightly soluble in water
|
| gptkbp:UNII |
U3P01618RT
|
| gptkbp:usedFor |
bipolar disorder
nausea schizophrenia vomiting tetanus acute psychosis intractable hiccups manic phase of bipolar disorder preoperative sedation |
| gptkbp:bfsParent |
gptkb:IG_Farben
|
| gptkbp:bfsLayer |
5
|